Want to see MNPR full AI Analyst Report?
MNPR Stock Chart & Stats
$109.87
$4.17(3.95%)
At close: 4:00 PM EDT
$109.87
$4.17(3.95%)
Day’s Range― - ―
52-Week Range$29.18 - $116.64
Previous CloseN/A
Volume229.82K
Average Volume (3M)206.37K
Market Cap
$730.80M
Enterprise Value$330.30
Total Cash (Recent Filing)$137.49M
Total Debt (Recent Filing)$131.56K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 06, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.07
Shares Outstanding6,699,062
10 Day Avg. Volume268,602
30 Day Avg. Volume206,371
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)3.51
Price to Sales (P/S)0.00
P/FCF Ratio-39.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$115.56Price Target Upside5.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress: Rolling NDAA permitted rolling NDA submission materially shortens regulatory timelines by enabling concurrent review of completed sections. This structural change reduces time-to-decision and preserves optionality for commercialization, improving the company's pathway to approval and long-term revenue prospects if accepted.
Pivotal Phase 3 EfficacyRobust Phase 3 results demonstrating superior, durable efficacy versus standard of care and favorable safety across substantial exposure (645 patient-years) materially strengthens the clinical value proposition. This durable efficacy profile supports higher approval probability and sustainable market position in a rare-disease niche.
Low Financial LeverageMinimal debt reduces fixed financial obligations and interest burden, preserving flexibility to fund ongoing development via equity or partnerships. Over a multi-month horizon this structural balance-sheet strength lowers bankruptcy risk and supports strategic choices for partnering or targeted financing.
Bears Say
Pre-revenue, Persistent LossesAs a development-stage biotech with no product revenues, the business model is structurally dependent on successful clinical and regulatory outcomes to generate cash. Persistent and materially worsening net losses limit internal funding capacity and heighten execution risk over the coming months absent external capital or a deal.
Worsening Cash BurnA step-up in cash outflows and sustained negative operating/free cash flow create measurable funding pressure. Over a 2–6 month horizon this raises the probability the company must access external capital or partnerships, which can constrain strategic flexibility and timeline for executing the development plan.
Reliance On External Financing / Equity ShiftsDramatic equity-base changes indicate recent financing dependence, a structural vulnerability for biotech developers. Repeated or large dilutive financings can erode shareholder value and create execution risk if capital markets tighten, making long-term program continuity contingent on funding access or partner deals.
Monopar Therapeutics Inc News
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $29.18 and its highest was $116.64 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is $730.80M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 6 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on May 14, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.721 by $0.261.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate is -0.66.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 6,699,062 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.721. Following the earnings report the stock price went down -0.732%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monopar Therapeutics Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$115.56 (5.17% Upside)
$115.56 (5.17% Upside)
Blogger Sentiment
Bullish
MNPR Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 152.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
150.49%
Trailing 12-Months
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
MNPR Stock 12 Month Forecast
Average Price Target
$115.56
▲(5.17% Upside)
Technical Analysis
Cardiff Oncology
―
Vanda
―
Verastem
―
Mereo Biopharma Group Plc
―
Silence Therapeutics
―
Ownership Overview
18.14% Insiders
6.76% Mutual Funds
0.12% Other Institutional Investors
67.98% Public Companies and
Individual Investors